Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Bought by BBR Partners LLC

BBR Partners LLC increased its position in Ikena Oncology, Inc. (NASDAQ:IKNA) by 550.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 130,000 shares of the company’s stock after acquiring an additional 110,000 shares during the period. BBR Partners LLC’s holdings in Ikena Oncology were worth $225,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Ikena Oncology during the 2nd quarter worth approximately $30,000. FMR LLC increased its position in Ikena Oncology by 94.1% during the third quarter. FMR LLC now owns 38,374 shares of the company’s stock worth $66,000 after buying an additional 18,607 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Ikena Oncology in the second quarter worth $36,000. Acadian Asset Management LLC raised its holdings in shares of Ikena Oncology by 15.2% in the second quarter. Acadian Asset Management LLC now owns 325,713 shares of the company’s stock worth $536,000 after acquiring an additional 42,931 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ikena Oncology in the second quarter valued at $75,000. 75.00% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on IKNA shares. HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Ikena Oncology in a research report on Monday, November 11th. Wedbush reissued a “neutral” rating and issued a $2.00 price objective on shares of Ikena Oncology in a research report on Thursday, November 7th.

Ikena Oncology Stock Down 1.2 %

IKNA stock opened at $1.69 on Thursday. The stock has a market capitalization of $81.56 million, a price-to-earnings ratio of -1.37 and a beta of 0.48. The stock’s fifty day simple moving average is $1.71 and its 200-day simple moving average is $1.67. Ikena Oncology, Inc. has a 52-week low of $1.22 and a 52-week high of $2.32.

Ikena Oncology (NASDAQ:IKNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.08. As a group, analysts anticipate that Ikena Oncology, Inc. will post -0.91 earnings per share for the current fiscal year.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.